Local pathways may vary
The remaining 35 states (Alabama, Alaska, Arkansas, Colorado, Connecticut, Delaware, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Oregon, Rhode Island, South Carolina, South Dakota, Utah, Vermont, West Virginia, Wisconsin, Wyoming) follow their state PDL more closely with fewer MCO carve-outs
As with all systemic small molecules there is also the potential for off-target toxicities and drug-drug interactions that need to be evaluated
Use as directed as part of a balanced diet and healthy lifestyle
This is about a common medication practice that may represent one exposure too many for infants already vulnerable from prenatal exposures